India’s pharma leadership and the people building AI for it, in the same room.
A new consortium, three to four editions a year, convened so that the people running pharma functions in India and the people building AI for them sit at the same table. The first edition is forthcoming. Applications are open.
Pharma and AI are in different rooms. We are putting them in the same one.
India is the third-largest pharmaceutical producer in the world. It supplies roughly twenty percent of the global generics market. The country has more than three thousand pharma companies, and roughly half of them are still at proof-of-concept stage with AI. The gap between where the industry is and where it needs to be is large, and closing.
That gap exists because two groups of professionals operate in separate rooms. Pharma people do not fully understand what AI can do for their specific function. AI and technology people do not fully understand what pharma professionals actually need. The result, everywhere else, is slow adoption, bad implementations, and a great deal of wasted potential on both sides.
AIforPharma is the structured space we are convening so that conversation happens. Three to four editions a year. Senior, curated, recurring. The relationships compound; the conversation carries forward.
- 01Chief Information Officers
- 02Chief Digital Officers
- 03Heads of R&D
- 04Heads of Regulatory
- 05Heads of Medical Affairs
- 06Heads of Pharmacovigilance
- 07Heads of Commercial
- 08Heads of Manufacturing and Quality
- 01Foundation-model companies
- 02Enterprise cloud platforms
- 03Data and observability vendors
- 04Pharma-focused AI startups
- 05AI engineering and product leaders
We invite by role and contribution, not by logo. The room is who’s in it; specific organisations get named in edition recaps, with permission.
Four things, on a deliberate cadence.
- I
Educates
Domain-specific working sessions on what AI is actually doing in pharma.
Sessions on R&D, regulatory, commercial, and medical affairs. Not theory: real workflows, named tools, real outcomes. A regulatory head and the engineer who built the submission-drafting model sit on the same panel.
- II
Connects
Pharma function leaders and the technology companies building for them, in the same conversation.
Editions are senior, curated, and small enough that the room can recognise itself. A regulatory head and the engineer who built the submission-drafting model sit on the same panel; a Brand Manager and the data-science lead at her cloud vendor sit on the next one. No vendor booths. No badge-scanning. Conversations begin in sessions and continue in side rooms, dinners, and follow-up calls.
- III
Showcases
Live demonstrations of AI applied to actual pharma problems.
Including PharmaOS, but not limited to it. Demos are real systems against real datasets, not slideware. Failures are discussed as candidly as successes.
- IV
Recurs
Three to four editions a year, so the conversation carries forward.
A consortium, not a conference. Between editions, the conversation lives in a private group of attendees. Each edition picks up from the last; the relationships compound rather than reset.
The largest pharma industry in the world, mid-way through its AI question.
- 3rdlargest pharmaceutical producer in the worldby volume; public industry data
- 3,000+pharma companies operating in Indiaacross formulations, APIs, and CDMOs
- 20%of the global generics market supplied from hereby volume; widely cited industry estimate
- ~50%of Indian pharma is reported to be at proof-of-concept stage with AIindustry observation, 2024–2025
The gap between where the industry is and where it needs to be is large, and the cost of closing it badly is high. AIforPharma exists so the closing happens with intention, in a room where both sides can recognise each other.
Edition 01 is being convened. Apply to be in the room.
The first edition will be single-day, single-room, and small enough that the room can recognise itself. Date and venue are being finalised and will be announced to invited applicants first. The application takes about seven minutes; the team reads every application in full.
- Single-day, single-room
- Senior attendees only
- Four working sessions, two demonstrations
- Curated dinner the evening prior
- Closed Chatham House rule
- R&D: where generative models actually help the bench
- Regulatory: AI-assisted ANDA drafting, in practice
- Commercial: MR-force productivity, primary-vs-secondary attribution, and the IQVIA layer
- Medical affairs: pharmacovigilance with foundation models
- Director-level or above at an operating pharma company in India
- Senior leadership at a technology company building for pharma
- Applications reviewed on a rolling basis
- All applicants receive a reply, one way or the other
Convened by the team behind PharmaOS, who were already in these conversations.
AIforPharma is organised by the team behind PharmaOS, a Super AI product that lets pharma companies query their own data in plain language. The consortium grew directly out of conversations the PharmaOS team was already having with R&D heads, regulatory leaders, and CIOs across the industry.
The conviction underneath the consortium is simple: the most useful version of this conversation does not happen in a vendor pitch, and it does not happen on a webinar. It happens between peers, in a room small enough to hold a real disagreement, on a schedule recurrent enough that the disagreement gets resolved by the next edition.
AIforPharma is not a product showcase. It is those conversations made public, with more of the right people in the room.
The edition is the highlight. The conversation is the product.
Between editions, the consortium will live in a private group of attendees. The intent is straightforward: a question on RAG over a regulatory document set gets answered by the person who built the retrieval pipeline at a peer company. A new CDSCO guidance lands and the group parses it together in real time. The next edition’s agenda is shaped by what the group has been arguing about for three months.
Membership in that group is extended to attendees after their first edition. It is moderated, off the record, and small enough to recognise itself. The group does not exist yet; it begins with the founding edition.
- Cadence
- editions a year, alternating cities
- Room size
- senior attendees per edition
- Format
- single room, Chatham House
- Entry
- reviewed by the organising team
Applications for the founding edition are open. Reviewed weekly.
Tell us where you sit, and why this room would be useful.
Applications take roughly seven minutes. They are reviewed by the organising team within seven days. Accepted applicants receive a formal invitation, along with the date and venue for the founding edition.
Begin the application- 01Your name, role, and organisation
- 02Which function you lead, and what AI question is on your desk right now
- 03Two sentences on what you would bring to the room
- 04Whether you would like to be part of the founding edition or wait for a later one
Not at director level yet, or working in adjacent fields (academic research, government, public health)? Write to room@aiforpharma.ai and we will route the request.